COPENHAGEN: Denmark’s Novo Nordisk on Monday stated it has agreed to purchase Cardior Prescription drugs for as much as 1.03 billion euros ($1.11 billion) to strengthen its cardiovascular pipeline. The acquisition is according to the Danish drugmaker’s goal to increase its concentrate on diabetes and weight-loss therapies to incorporate heart…